CRIS Current Research Information System

OTTAVIANI, EMANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.435
AS - Asia 7.154
EU - Europa 6.955
AF - Africa 563
SA - Sud America 413
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 9
Totale 23.543
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.346
CN - Cina 2.157
SG - Singapore 2.055
GB - Regno Unito 2.038
VN - Vietnam 1.539
SE - Svezia 1.198
DE - Germania 868
IT - Italia 840
HK - Hong Kong 501
IN - India 381
RU - Federazione Russa 356
FR - Francia 292
BR - Brasile 287
IE - Irlanda 257
NL - Olanda 216
KR - Corea 175
UA - Ucraina 162
ZA - Sudafrica 155
TG - Togo 146
EE - Estonia 133
FI - Finlandia 131
NG - Nigeria 103
CH - Svizzera 99
GR - Grecia 95
CI - Costa d'Avorio 92
BG - Bulgaria 79
JO - Giordania 77
CA - Canada 62
AR - Argentina 61
BE - Belgio 57
JP - Giappone 54
SC - Seychelles 50
IR - Iran 46
AT - Austria 37
PL - Polonia 34
ID - Indonesia 30
TR - Turchia 26
BD - Bangladesh 23
EC - Ecuador 19
ES - Italia 19
MX - Messico 19
IQ - Iraq 15
UZ - Uzbekistan 13
AU - Australia 11
CL - Cile 10
PE - Perù 10
PH - Filippine 9
PY - Paraguay 9
LB - Libano 8
MY - Malesia 8
RO - Romania 8
CO - Colombia 7
EU - Europa 7
LT - Lituania 6
PT - Portogallo 6
MA - Marocco 5
AE - Emirati Arabi Uniti 4
KZ - Kazakistan 4
MK - Macedonia 4
PK - Pakistan 4
CZ - Repubblica Ceca 3
GY - Guiana 3
IL - Israele 3
KE - Kenya 3
KG - Kirghizistan 3
NZ - Nuova Zelanda 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
TN - Tunisia 3
UY - Uruguay 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
DK - Danimarca 2
EG - Egitto 2
ET - Etiopia 2
GT - Guatemala 2
HR - Croazia 2
LV - Lettonia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AM - Armenia 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CR - Costa Rica 1
CY - Cipro 1
DZ - Algeria 1
GE - Georgia 1
HN - Honduras 1
HU - Ungheria 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MU - Mauritius 1
NO - Norvegia 1
NP - Nepal 1
Totale 23.537
Salva come PNG Salva come JPEG
Città #
Southend 1.887
Singapore 1.342
Ashburn 924
Dong Ket 917
Chandler 841
Fairfield 820
Hong Kong 497
Houston 465
Wilmington 408
Hefei 393
Woodbridge 388
Seattle 381
Beijing 380
Ann Arbor 375
Princeton 319
Santa Clara 296
Cambridge 295
Dublin 256
Boardman 214
Westminster 164
Seoul 160
Bologna 158
Padova 156
Lomé 146
Nanjing 143
Los Angeles 114
Medford 111
New York 111
Helsinki 104
Ho Chi Minh City 100
Abidjan 92
Hanoi 86
Bern 81
Saint Petersburg 79
Jinan 78
Amman 77
Sofia 77
Shenyang 75
Milan 70
Abeokuta 69
Munich 69
Bremen 65
Hebei 62
Berlin 60
Dallas 59
Buffalo 58
Jacksonville 58
Brussels 56
Nanchang 56
Redondo Beach 55
Changsha 52
San Diego 49
Turin 49
Frankfurt am Main 48
Tokyo 46
São Paulo 42
Redwood City 38
Florence 37
Bengaluru 36
Tianjin 36
Jiaxing 35
Falls Church 34
Zhengzhou 30
Guangzhou 28
Shanghai 27
Hangzhou 25
Toronto 24
Rome 23
Falkenstein 22
Turku 22
Ningbo 21
Norwalk 21
Vienna 21
Athens 20
London 19
Taizhou 19
Mountain View 18
Taiyuan 18
Xi'an 18
Paris 17
Mülheim 16
Orem 16
Phoenix 16
Tongling 16
Chengdu 15
Grafing 15
Istanbul 15
Jakarta 15
Mahé 15
Olalla 15
Zanjan 15
Dearborn 14
Fuzhou 14
Leawood 14
Nuremberg 14
Boston 13
Chennai 13
Düsseldorf 13
Haikou 13
Warsaw 13
Totale 15.432
Salva come PNG Salva come JPEG
Nome #
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 321
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 317
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 315
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 306
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 286
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 271
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 260
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 232
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 228
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 219
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 216
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 213
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 213
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 211
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 208
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 206
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 203
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 202
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 202
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 201
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 201
Assessment of the interlaboratory variability and robustness of JAK2V617Fmutation assays: A study involving a consortium of 19 Italian laboratories 200
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 197
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 197
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 196
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 194
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 184
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 181
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 176
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 176
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 174
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 173
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 173
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 173
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 170
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 170
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 169
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 169
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 169
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 167
Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. 166
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 165
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 164
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 164
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 164
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 164
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 160
NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. 159
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 159
Clec12a: A new AML stem cell-associated antigen 158
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 158
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 154
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 154
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 154
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 154
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 153
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 152
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 152
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 152
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 151
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 151
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 150
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 150
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 148
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 148
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 147
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 146
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 146
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 146
A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 146
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 145
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 144
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 144
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 144
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 144
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. 143
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 141
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 139
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia 139
THE RS564398, A POLYMORPHISM IN “THE ANTISENSE NON-CODING RNA IN THE INK4 LOCUS”, ANRIL, IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) SUSCEPTIBILITY 139
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 138
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 138
Pediatric-Like Intensified Therapy In Adult Acute Lymphoblastic Leukemia: A Single Centre Experience 136
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 136
May the correlation between Kit-D816 mutation and AML1-ETO level change the use of prognostic factors in t(8;21) AML? 133
Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia 133
SNP array reveals a new deletion of JAK2 in AML patients 133
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 132
Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients 132
You have accessA New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 132
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. 132
Genomic wide microarray analysis identifies novel copy number alterations in adult acute myeloid leukemia 131
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 130
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 129
Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients 129
GENETIC VARIATIONS IN ADH1A AND CYP2E1 STRONGLY AFFECTS RESPONSE AND TOXICITY TO A COMBINATION OF GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS 128
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 128
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 128
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin 128
PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment. 127
Totale 17.129
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.186
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.186
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.939 0 0 0 0 0 0 72 164 222 112 108 1.261
2021/20223.331 357 70 216 322 329 221 58 187 150 255 597 569
2022/20233.509 416 568 174 487 225 282 107 193 569 86 254 148
2023/2024914 35 149 39 91 49 211 61 64 59 45 63 48
2024/20253.570 137 548 292 249 459 154 331 106 35 318 164 777
2025/20264.197 746 772 720 542 940 475 2 0 0 0 0 0
Totale 24.010